SCM
ACAD icon

Stonepine Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Stonepine Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Buy
+100,000
New +$2.39M 0.89% 18

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Stonepine Capital Management's ACAD Position: Q1 2026 in Review

Stonepine Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 100,000 shares — an estimated $2.39M sold.

Stonepine Capital Management first reported a position in ACAD in Q2 2018 and held it in 8 quarters. The position peaked at $4.85M in Q2 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Stonepine Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 100,000 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.39M.
  • Stonepine Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • Stonepine Capital Management's Acadia Pharmaceuticals position peaked at $4.85M in Q2 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.